Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors.

@article{Danesi2009PharmacogenomicsOG,
  title={Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors.},
  author={Romano Danesi and Giuseppe Altavilla and Elisa Giovannetti and R. Rosell},
  journal={Pharmacogenomics},
  year={2009},
  volume={10 1},
  pages={
          69-80
        }
}
The validation of predictive biomarkers to tailor chemotherapy is a key issue in the development of effective treatment modalities against cancer. Examples of how genetics might affect drug response are offered by gemcitabine. A substantial number of potential biomarkers for sensitivity or resistance to gemcitabine have been proposed, including ribonucleotide reductase and cytidine deaminase polymorphisms, human equilibrative transporter-1 and ribonucleotide reductase gene-expression and AKT… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 26 CITATIONS

miR-206/133b Cluster: A Weapon against Lung Cancer?

  • Molecular therapy. Nucleic acids
  • 2017
VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED